TY - CHAP M1 - Book, Section TI - Perioperative Management of Kidney Disease A1 - Cheng, Hugo Q. A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. PY - 2021 T2 - Current Medical Diagnosis & Treatment 2021 AB - Approximately one-third of patients undergoing general surgery will suffer some degree of acute kidney injury, and 3% of patients will develop a creatinine elevation greater than 2 mg/dL (176.8 mcmol/L) above baseline or require renal replacement therapy. The development of acute kidney injury is an independent predictor of mortality, even if mild or if kidney dysfunction resolves. The mortality associated with the development of perioperative acute kidney injury that requires dialysis exceeds 50%. Risk factors associated with postoperative deterioration in kidney function are shown in Table 3–8. Several medications, including “renal-dose” dopamine, mannitol, N-acetylcysteine, and clonidine, have been evaluated in an attempt to preserve kidney function during the perioperative period. None of these has proved effective in clinical trials and should not be used for this indication. Maintenance of adequate intravascular volume is likely to be the most effective method to reduce the risk of perioperative deterioration in kidney function. Exposure to renal-toxic agents, such as nonsteroidal anti-inflammatory drugs and intravenous contrast, should be minimized or avoided. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce renal perfusion and may increase the risk of perioperative acute kidney injury. Although firm evidence is lacking, it may be useful to temporarily discontinue these medications in patients at risk for perioperative acute kidney injury. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2023/01/26 UR - accessmedicine.mhmedical.com/content.aspx?aid=1175790622 ER -